Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Antibody drug conjugate

- PMLiVE

AbbVie sells $30bn of bonds ahead of Allergan merger

Will use net proceeds to fund cash consideration due to shareholders

Understanding the evolving CAR-T market

In 2017 the approval of the first CAR-T treatment took the world by storm, transforming the way cancer is treated, but two years later more than 500 CAR-Ts are in...

Blue Latitude Health

China flag thumb

Amgen buys BeiGene stake for $2.7bn to aid push into China

China's oncology market forecast to nearly double in size by 2026

- PMLiVE

Pfizer raises forecast following growth of biopharma business

On the flip-side company reported decline in Upjohn generics division

AstraZeneca AZ

AZ reports growth again in Q3, driven by oncology and China sales

Company has also returned to growth in Europe

AstraZeneca AZ

AstraZeneca sells Losec rights as part of refocus strategy

Funds will be diverted to bolster main therapy areas

- PMLiVE

AbbVie/Allergan’s merger faces public opposition

Advocacy groups and unions in the US express concerns

- PMLiVE

Strike three for Rova-T has AbbVie cutting its losses

Will funnel R&D money into more promising projects

- PMLiVE

‘Therapeutic overcrowding’ could hit big pharma returns

Jefferies analysts identify most at-risk companies

- PMLiVE

AbbVie scores FDA approval for arthritis treatment upadacitinib

Could find it difficult to live up to Humira

- PMLiVE

Imbruvica gains expanded use in Europe

Rival Calquence receives accelerated review in US

- PMLiVE

GSK hires Merck KGaA exec to lead US pharma business

Martinez-Davis will help strengthen company’s oncology focus

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links